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Abstract
Introduction Recognition that an older person has sarcopenia is important because this condition is linked to a range of
adverse outcomes. Sarcopenia becomes increasingly common with age, and yet there are few data concerning its descriptive
epidemiology in the very old (aged 85 years and above). Our aims were to describe risk factors for sarcopenia and estimate its
prevalence and incidence in a British sample of the very old.
Methods We used data from two waves (2006/07 and 2009/10) of the Newcastle 85+ Study, a cohort born in 1921 and
registered with a Newcastle/North Tyneside general practice. We assessed sarcopenia status using the European Working
Group on Sarcopenia in Older People (EWGSOP) definition. Grip strength was measured using a Takei digital dynamometer
(Takei Scientific Instruments Ltd., Niigata, Japan), gait speed was calculated from the Timed Up and Go test, and lean mass
was estimated using a Tanita-305 body fat analyzer. We used logistic regression to examine associations between risk factors
for prevalent sarcopenia at baseline and incident sarcopenia at follow-up.
Results European Working Group on Sarcopenia in Older People sarcopenia was present in 21% of participants at baseline
[149/719 participants, mean age 85.5 (0.4) years]. Many participants had either slow gait speed or weak grip strength (74.3%),
and hence measurement of muscle mass was frequently indicated by the EWGSOP definition. Incidence data were available
for 302 participants, and the incident rate was 3.7 cases per 100 person years at risk. Low Standardized Mini-Mental State
Examination, lower occupational social class, and shorter duration of education were associated with sarcopenia at baseline,
while low muscle mass was associated with incident sarcopenia. Low body mass index (BMI) was a risk factor for both in a
graded fashion, with each unit decrease associated with increased odds of prevalent [odds ratio (OR) 1.29, 95% confidence
interval (CI): 1.21, 1.37] and incident (OR 1.20, 95% CI: 1.08, 1.33) sarcopenia.
Conclusions To our knowledge, this is the first study to describe prevalence and incidence of EWGSOP sarcopenia in the very
old. Low BMI was a risk factor for both current and future sarcopenia; indeed, there was some evidence that low BMI may be a
reasonable proxy for low lean mass. Overall, the high prevalence of sarcopenia among the very old suggests that this group
should be a focus for future research.
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Introduction
Sarcopenia is the loss of muscle mass and function that
occurs with ageing, and this condition has been associated
with a range of adverse outcomes including disability.1 A
commonly used approach to diagnosis is that proposed by
the European Working Group on Sarcopenia in Older People
(EWGSOP), where the presence of slow gait speed or weak
grip strength is an indication to test for low muscle mass.2
Those aged 80 years and above represent the fastest growing
sector of the population worldwide3 and the focus of many
clinicians who care for older people, and yet there are few
data concerning the descriptive epidemiology of sarcopenia
in the very old. For example, in a recent systematic review
of 18 studies of sarcopenia prevalence,4 all but two had a
mean age under 85 years. This may reflect the challenges
of studying sarcopenia in the very old, such as the time
required for assessment and factors such as medical illness
that may make it difficult to obtain a representative sample.5
Estimates of prevalence are useful for the planning of ser-
vices and clinical research. Such studies can also be used to
identify risk factors for sarcopenia and hence which groups
may stand to benefit most from assessment and interven-
tion. There is also little published research on the incidence
of sarcopenia, and existing studies have typically been
conducted at mean ages below 75.6,7 Our aims were
therefore to estimate the prevalence and incidence of
sarcopenia and to examine risk factors for both using a
British sample of the very old.
Methods
Participants
We used data from two waves (2006/07, Wave 1 and
2009/10, Wave 3) of the Newcastle 85+ Study. Full details
of the study have been published previously8,9; in brief, the
cohort were born in 1921 and were recruited to the study
through Newcastle/North Tyneside general practices at
around age 85. Of the 1040 people recruited to the study,
845 completed a multidimensional health assessment by a
trained research nurse at their usual place of residence
(whether this was at home or in an institution) and had a
review of their general practice records. Ethical approval
was obtained from Newcastle and North Tyneside Local
Research Ethics Committee One, and informed written
consent was obtained from all participants.
Assessment of sarcopenia status
We assessed sarcopenia status at baseline and 3 year follow-
up using the EWGSOP definition2: slow gait speed or weak
grip strength are indications to test for low muscle mass,
which if present confirms the diagnosis of sarcopenia. Gait
speed was not measured directly in Newcastle 85+ Study,
although the Timed Up and Go (TUG) test was included: a
stopwatch was used to measure the time taken to get up
from a chair and walk as quickly and safely as possible up
to and around a marker placed 3m away, walk back to the
chair, and sit back down. We converted this time to an
estimate of gait speed using the formula [6/(TUG time)]
*1.62.10,11 We used the standard cut-off of ≤0.8m/s for slow
gait speed.2
Hand grip strength (kg) was measured using a Takei A5401
digital dynamometer (Takei Scientific Instruments Ltd.,
Niigata, Japan) in the standing position, with two trials from
each hand alternately. We used the maximum of the available
measures for analyses. We used the cut-offs for weak grip
strength derived by the Foundation for the National Institute
of Health (FNIH) sarcopenia project, <16 kg in women and
<26 kg in men.12
We assessed muscle mass using bioimpedance values
measured with a Tanita-305 body fat analyzer (Tanita Corp.,
Tokyo, Japan). Participants were measured standing with
bare feet placed on the metal sole plates of the device.13
We used the formula developed by Jansen et al.14 to
estimate skeletal muscle index (SMI, skeletal muscle mass
divided by height squared, kg/m2) values in the participants.
We used previously published cut-offs for low SMI of
<8.87 kg/m2 and <6.67 kg/m2 in men and women,
respectively.2,15
Potential risk factors for sarcopenia
We identified potential risk factors for prevalent and
incident sarcopenia a priori at wave 1 that we considered
to be clinically relevant. These included difficulty with
activities of daily living (ADLs, both basic and instrumen-
tal16), living in sheltered or institutional accommodation,
the number of longstanding illnesses17 and prescribed
medications, Standardized Mini-Mental State Examination
(SMMSE) score, Geriatric Depression Scale (GDS), body mass
index (BMI), smoking history, self-reported physical activity,18
occupational social class (or their partner’s, where they were
the main earner), and years of education. We also
examined if pre-sarcopenia (low muscle mass with
normal gait speed and grip strength2) was a risk factor for
incident sarcopenia.
Statistical analyses
We considered that those unable to complete the TUG or
grip strength measures due to health problems had low
performance for the purpose of analyses. We used
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univariable logistic regression to examine associations be-
tween each risk factor and prevalent sarcopenia at baseline
and incident sarcopenia at follow-up. We set our level for
statistical significance as P< 0.05. We considered it likely
that many of those who died before follow-up had devel-
oped sarcopenia prior to their death. We therefore repeated
our incidence analyses using a combined end-point of
sarcopenia and death. We performed all analyses using Stata
version 14.0.19
Results
We were able to assign a status of normal or low to the gait
speed, grip strength, and muscle mass of 719 participants at
baseline (85% of those who underwent health assessment
and GP record review), including those who were unable to
complete the TUG (n = 4) or grip strength (n = 2) tests due to
health reasons. The characteristics of those included in the
study are shown in Table 1. The majority were women
Table 1 Distribution of risk factors by sarcopenia status
Risk factor
All No sarcopenia Sarcopenia
(n=719 unless shown otherwise) No. (%) No. (%) No. (%)
Gender
Male 282 (39.2) 223 (39.1) 59 (39.6)
Female 437 (60.8) 347 (60.9) 90 (60.4)
ADLs with difficulty (n=713)
None 156 (21.9) 131 (23.1) 25 (17.1)
1–5 352 (49.4) 280 (49.4) 72 (49.3)
6 or more 205 (28.8) 156 (27.5) 49 (33.6)
Type of housing
Standard 593 (82.5) 474 (83.2) 119 (79.9)
Sheltered 119 (16.6) 90 (15.8) 29 (19.5)
Institution 7 (1.0) 6 (1.1) 1 (0.7)
Disease count
0 or 1 212 (29.5) 168 (29.5) 44 (29.5)
2 219 (30.5) 175 (30.7) 44 (29.5)
3 or more 288 (40.1) 227 (39.8) 61 (40.9)
Total prescribed medications
0–4 242 (33.7) 192 (33.7) 50 (33.6)
5–7 239 (33.2) 194 (34.0) 45 (30.2)
8 or more 238 (33.1) 184 (32.3) 54 (36.2)
SMMSE (n=718)
26–30 (normal) 545 (75.9) 444 (78.0) 101 (67.8)
21–25 (mild impairment) 124 (17.3) 90 (15.8) 34 (22.8)
0–20 (severe impairment) 49 (6.8) 35 (6.2) 14 (9.4)
GDS (if SMMSE ≥15) (n=716)
0–5 (no depression) 563 (78.6) 453 (79.8) 110 (74.3)
6–7 (mild depression) 85 (11.9) 64 (11.3) 21 (14.2)
8 or more (severe depression) 52 (7.3) 40 (7.0) 12 (8.1)
(SMMSE <15) 16 (2.2) 11 (1.9) 5 (3.4)
BMI (kg/m2) (n=716)
Under 18.5 46 (6.4) 19 (3.4) 27 (18.1)
18.5–24.9 369 (51.5) 271 (47.8) 98 (65.8)
25 or above 301 (42.0) 277 (48.9) 24 (16.1)
Smoking status (n=718)
Never 245 (34.1) 193 (33.9) 52 (35.1)
Current 42 (5.8) 29 (5.1) 13 (8.8)
Former 431 (60.0) 348 (61.1) 83 (56.1)
Physical activity (n=717)
Low 132 (18.4) 94 (16.5) 38 (25.5)
Medium 319 (44.5) 256 (45.1) 63 (42.3)
High 266 (37.1) 218 (38.4) 48 (32.2)
Own/partner’s occupation (n=694)
Managerial/professional 241 (34.7) 203 (36.9) 38 (26.4)
Intermediate 83 (12.0) 66 (12.0) 17 (11.8)
Routine/manual 370 (53.3) 281 (51.1) 89 (61.8)
Years in education (n=715)
0–9 459 (64.2) 359 (63.3) 100 (67.6)
10–11 166 (23.2) 129 (22.8) 37 (25.0)
12–20 90 (12.6) 79 (13.9) 11 (7.4)
ADLs, activities of daily living; BMI, body mass index; GDS, Geriatric Depression Scale; SMMSE, Standardized Mine-Mental State
Examination.
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(61%), had difficulty with between one and five ADLs, and
had three or more chronic diseases. Mean BMI was 24.4
(4.4) kg/m2.
Prevalence and incidence of sarcopenia
The overall prevalence of sarcopenia at baseline was 21% at
mean age 85.5 (0.4) years, with similar findings in men and
women. Mean estimated gait speed (m/s) was 0.8 (0.3) and
0.7 (0.3) in men and women, respectively, whereas mean grip
strength (kg) was 27.3 (7.1) and 15.3 (4.8). These mean
values were similar to the sarcopenia cut-points used, with
74% of participants falling below one or both and therefore
requiring assessment of muscle mass by the EWGSOP defini-
tion (Figure 1). Mean estimated SMI (kg/m2) was 9.9 (1.8) in
men and 7.7 (2.2) in women, with 28% of participants falling
below the cut-points used.
Follow-up data were available for 302 of the 570 partici-
pants at baseline without sarcopenia. There were 149 with-
drawals from the study because of death as shown in
Figure 2. The mean follow-up time was 2.99 (0.04) years,
and there were 33 incident cases of sarcopenia: an incidence
rate of 3.66 cases per 100 person years at risk.
Risk factors for sarcopenia
The associations of the potential risk factors with prevalent
and incident sarcopenia are shown in Table 2. We saw that
those with evidence of cognitive impairment (MMSE <26)
were at increased risk of prevalent sarcopenia (OR 1.64
(95% CI: 1.07, 2.52), P = 0.03), while those with normal or
raised BMI were at reduced risk. Participants with BMI 25
or above had 14 times lower odds [OR 0.07 (95% CI: 0.03,
0.15), P< 0.01] than those with BMI <18.5. There was also
evidence that those whose occupation (or partner’s
Figure 1 Overlap between sarcopenia components at baseline. This fig-
ure shows the number of participants from the baseline assessment (to-
tal n=719) with each combination of slow gait, weak grip, and low
skeletal muscle index (SMI). The percentage of the total sample with a
low value for each of the three measures is shown in brackets.
Figure 2 Flow diagram of participants. Only potential incident cases are shown at follow-up, that is, those participants without sarcopenia at baseline.
‘Asterisks’, other reasons for withdrawal included ill health, fatigue, and losing interest in the study.
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occupation) was routine/manual were at increased risk, as
were those with fewer than 12 years in education.
In terms of incident sarcopenia, higher BMI again appeared
protective with an OR of 0.17 (95% CI: 0.04, 0.77), P< 0.01.
The presence of low SMI, or pre-sarcopenia, at baseline was
also strongly associated with incident sarcopenia (OR 8.28
(95% CI: 3.64, 18.84), P< 0.01). We repeated our analyses
using a combined outcome of incident sarcopenia or death.
As shown in Appendix 1, we found strong positive relation-
ships with multiple risk factors: ADL disability, living in shel-
tered housing, number of chronic diseases, number of
prescription medications, lower MMSE, higher GDS,
Table 2 Association between risk factors and prevalent/incident sarcopenia
Association between risk factor and outcome shown
Prevalent sarcopenia (n=664)a Incident sarcopenia (n=290)b
Risk factor OR (95% CI) P OR (95% CI) P
Gender 0.77 0.59
Male 1 1
Female 1.06 (0.72, 1.56) 1.23 (0.58, 2.60)
ADLs with difficulty 0.37 0.04
None 1 1
1–5 1.37 (0.83, 2.28) 1.55 (0.69, 3.52)
6 or more 1.45 (0.83, 2.56) 0.23 (0.03, 1.86)
Type of housingc 0.39 0.36
Standard 1 1
Sheltered 1.26 (0.75, 2.10) 1.66 (0.59, 4.68)
Disease count 0.99 0.67
0 or 1 1 1
2 0.96 (0.59, 1.57) 1.01 (0.43, 2.38)
3 or more 0.98 (0.62, 1.55) 0.7 (0.28, 1.75)
Total prescribed medications 0.83 0.83
0–4 1 1
5–7 0.88 (0.55, 1.40) 0.78 (0.33, 1.82)
8 or more 1 (0.63, 1.58) 0.83 (0.33, 2.07)
SMMSEc 0.03 0.16
26–30 (normal) 1 1
15–25 1.64 (1.07, 2.52) 0.4 (0.09, 1.73)
GDSc 0.61 0.09
0–5 (no depression) 1 1
6–7 (mild depression) 1.31 (0.75, 2.29) 3.27 (1.18, 9.10)
8 or more (severe depression) 1.17 (0.58, 2.36) 0.62 (0.08, 4.94)
BMI (kg/m2) <0.01 <0.01
Under 18.5 1 1
18.5–24.9 0.29 (0.15, 0.56) 0.77 (0.20, 2.95)
25 or above 0.07 (0.03, 0.15) 0.17 (0.04, 0.77)
Smoking status 0.13 0.22
Never 1 1
Current 1.99 (0.95, 4.18) 2.89 (0.52, 16.04)
Former 0.93 (0.62, 1.41) 1.99 (0.82, 4.79)
Physical activityc 0.31 0.55
Low/medium 1 1
High 0.82 (0.55, 1.21) 1.25 (0.60, 2.58)
Own/partner’s occupation 0.03 0.16
Managerial/professional 1 1
Intermediate 1.3 (0.67, 2.53) 1.26 (0.37, 4.34)
Routine/manual 1.76 (1.14, 2.73) 2.16 (0.94, 4.96)
Years in education 0.08 0.59
0–9 1 1
10–11 0.85 (0.53, 1.34) 0.85 (0.34, 2.09)
12–20 0.48 (0.24, 0.96) 0.58 (0.19, 1.75)
Pre-sarcopenia (incidence only) <0.01
SMI above cut-points 1
SMI below cut-points 8.28 (3.64, 18.84)
ADLs, activities of daily living; BMI, body mass index; GDS, Geriatric Depression Scale; SMMSE, Standardized Mine-Mental State
Examination.
an=664 (of 719) in the prevalence sample with complete information on risk factors shown.
bn=290 (of 302) in the incidence sample with complete information on risk factors shown.
cThe smaller sample for the incidence analyses meant levels of some variables had too few participants for inclusion or predicted the out-
come exactly. We therefore removed those unable to complete the GDS as their MMSE was below 15 and those living in institutions. These
changes excluded 14 participants from the prevalence analyses. We also grouped those remaining with MMSE <26 together and those
with low/medium physical activity together.
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low/medium physical activity, lower occupational class, and
shorter duration of education. We no longer saw the relation-
ships with low BMI and low SMI when death was included as
an alternative outcome alongside sarcopenia.
Discussion
Summary of findings
To our knowledge, this is the first study to describe preva-
lence and incidence of EWGSOP-defined sarcopenia in those
aged 85 years and over. Sarcopenia was present in 21% of
the participants at baseline. Of those without sarcopenia at
baseline, approximately 10% developed sarcopenia at
follow-up after an average of 3 years. Low BMI predicted both
prevalent and incident sarcopenia, whereas other risk factors
such as number of chronic diseases showed less evidence of
an association. There was also substantial loss to follow-up,
mainly due to death. When we included death as an alterna-
tive outcome alongside incident sarcopenia, we saw much
stronger relationships with the risk factors examined.
Interpretation of findings
The Newcastle 85+ Study was broadly representative at base-
line of those born in 1921 and registered with a Newcastle
upon Tyne or North Tyneside general practice.9 We included
the majority of the baseline sample, although there were
exclusions, particularly among those living in institutions; this
group made up 1% of our sample at baseline, compared with
5% of those who took part in the study. As such, it seems
likely that the true prevalence of sarcopenia may be higher
than 21%.
We are aware of four other studies that have examined
the prevalence of EWGSOP sarcopenia at mean age 85 years
or above. Their findings varied, but in all four there was a
high proportion of individuals (81% or greater) who fell below
gait speed and grip strength cut-points and therefore
required assessment of muscle mass. Legrand et al.20 found
a prevalence of 12.5% in a Belgian sample at mean age 84.8
(3.6) years using bioelectrical impedance analysis (BIA) to
assess muscle mass. Landi et al.21 and Senior et al.22 also
used BIA and found prevalences of 32.8% and 40.2% among
residents in nursing homes at mean ages 84.1 (6.9) and
84.5 (8.2) years, respectively. Finally, Landi et al.23 used
mid-arm muscle circumference to estimate muscle mass
and found a prevalence of 29.1% in an Italian sample at mean
age 85.8 (4.9) years.
We are not aware of other studies that have examined
the incidence of EWGSOP sarcopenia in this age group. Of
those without sarcopenia at baseline who completed
follow-up, we saw an average annual incidence of 3.6%. This
is similar to the annual incidence of 3.4% found by Yu et al.
in a Chinese sample aged 72.5 (5.2) years at baseline.6 There
were also approximately four times as many participants lost
to follow-up because of death as there were incident cases
of sarcopenia. It is likely that a substantial proportion of
those who died had developed sarcopenia prior to their
death24, and hence our incidence rate may also be an
underestimate.
In terms of risk factors for sarcopenia, we saw evidence of
cross-sectional associations with low SMMSE, low socio-
economic position, and especially with low BMI. This mirrors
other findings in this age group21,22 in which an association
with higher levels of ADL disability has also been found.20
In longitudinal analyses in our study (n = 290), low BMI and
low SMI were clearly associated with sarcopenia. In the study
by Yu et al. (n = 2898 for 4 year follow-up of incident
sarcopenia), associations were also found with impairments
of instrumental ADLs, lower physical activity, and the pres-
ence of chronic obstructive pulmonary disease and stroke.6
It may be that there are also associations with these factors
in our sample population, but that our study is inadequately
powered to detect them.
The strong relationships between BMI and sarcopenia,
both prevalent and incident, deserve further consideration.
These appear to have arisen in our sample because the pres-
ence or absence of sarcopenia was largely dependent on SMI
status (as described earlier). In turn, BMI is positively corre-
lated with SMI, with low SMI being uncommon at BMI 25
and above. Indeed, it has previously been suggested that
skeletal muscle mass estimated from bioimpedance provides
little additional information regarding body composition than
that from BMI.25 In additional analyses (not shown), we
included both low SMI and BMI in the same model, and both
remained significantly associated with incident sarcopenia.
This would suggests that SMI estimated from bioimpedance
provides useful information on muscle mass in addition to
that from BMI, and that both are risk factors for the develop-
ment of sarcopenia.
Strengths and limitations
This study may have been underpowered to detect associa-
tions with potential risk factors, particularly for incident
sarcopenia. We also used BIA when dual energy X-ray absorp-
tiometry (DEXA) is the preferred method for assessment of
muscle mass.2 However, BIA has been used in other studies
and has the advantage that the equipment is portable.
Strengths of this study include the extensive efforts during
the Newcastle 85+ Study fieldwork to recruit a representative
sample of general practices and participants and to record
reasons for non-participation with measures such as grip
strength. We also included withdrawal due to death as a
competing risk in our analyses on incident sarcopenia.
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Implications for clinical practice and future research
This study adds to the existing literature which suggests that
the assessment of EWGSOP sarcopenia is feasible in the very
old, at least in a research setting. The high prevalence of indi-
viduals requiring assessment of muscle mass is a challenge,
particularly if the hospital-based technique of DEXA is to be
used.26 There was some suggestion from our results that
BMI could be used as an initial screen for those likely to have
low skeletal muscle mass before undertaking formal testing.
There is also interest in using questionnaire-based measures
such as the SARC-F tool to screen those who require further
assessment of possible sarcopenia.27
We found that several common clinical factors such as
number of prescribed medications were not associated with
prevalent and/or incident sarcopenia. This may be because
our study lacked sufficient power to detect such associations.
By contrast, when we included study withdrawal due to
death as an alternative outcome alongside incident
sarcopenia, we saw clear associations with many of the risk
factors tested (Appendix 1). This highlights a challenge of ex-
ploring risk factors for incidence in this age group, where sur-
viving to follow-up and undergoing assessment of disease
status is likely to be a marker of better overall health.
The Foundation for the National Institutes of Health Bio-
markers Consortium have developed cut-points for grip
strength and for appendicular lean mass divided by body mass
index (ALMBMI).
28 They undertook validation of the cut-points
in terms of mortality and incident disability and recommended
that further validation studies for each measure be carried
out.29 The findings from the present study support this ap-
proach and also highlight the need to conduct analyses that in-
corporate competing risks (such as mortality) in the very old.
Conclusions
We investigated the prevalence and incidence over 3 years of
sarcopenia using the EWGSOP definition in a representative
sample of the very old, the Newcastle 85+ Study. There
was a high prevalence of sarcopenia and a high incidence
of sarcopenia or death during follow-up. We explored a
range of risk factors and saw the strongest relationships with
low BMI. This is of potential clinical relevance, especially
when measurement of muscle mass may not be feasible.
The high prevalence of sarcopenia among the very old sug-
gests that this group should be a particular focus for future
research.
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Appendix
Association between risk factors and combined outcome of incident sarcopenia or death
Association between factor shown and incident sarcopenia or death (n=424)2
Risk factor OR (95% CI) P
Gender 0.32
Male 1 (1.00, 1.00)
Female 0.82 (0.55, 1.22)
ADLs with difficulty <0.01
None 1 (1.00, 1.00)
1–5 2.22 (1.30, 3.79)
6 or more 5.35 (2.90, 9.86)
Type of housing <0.01
Standard 1
Sheltered 2.29 (1.30, 4.01)
Disease count 0.01
0 or 1 1
2 1.01 (0.60, 1.71)
3 or more 1.84 (1.15, 2.97)
Total prescribed medications <0.01
0–4 1
5–7 1.4 (0.86, 2.29)
8 or more 2.36 (1.45, 3.84)
SMMSE 0.01
26–30 (normal) 1
25 or below 1.93 (1.17, 3.19)
GDS (if MMSE ≥15) <0.01
0–5 (no depression) 1
6–7 (mild depression) 2.93 (1.51, 5.66)
8 or more (severe depression) 1.93 (0.90, 4.13)
BMI (kg/m2) 0.22
Under 18.5 1
18.5–24.9 1.22 (0.45, 3.26)
25 or above 0.85 (0.32, 2.29)
Smoking status 0.03
Never 1
Current 2.53 (0.95, 6.70)
Former 1.7 (1.09, 2.64)
Physical activity <0.01
Low/medium 1
High 0.5 (0.33, 0.75)
Own/partner’s occupation 0.06
Managerial/professional 1
Intermediate 0.96 (0.51, 1.83)
Routine/manual 1.6 (1.05, 2.44)
Years in education 0.02
0–9 1
10–11 0.92 (0.57, 1.48)
12–20 0.42 (0.22, 0.79)
Pre-sarcopenia 0.2
SMI above cut-points 1
SMI below cut-points 1.53 (0.80, 2.92)
ADLs, activities of daily living; BMI, body mass index; GDS, Geriatric Depression Scale; SMMSE, Standardized Mine-Mental State
Examination.
n=424 (of 451) in the sample with follow-up for incident sarcopenia (or death before follow-up) and complete information on risk fac-
tors shown.
We also repeated the aforementioned analyses with deaths within 6months of the baseline assessment excluded (n=14) to see if any of
the aforementioned associations were reflective of pre-terminal illness. The results were unchanged when we did this.
Prevalence and incidence of sarcopenia in the very old 9
Journal of Cachexia, Sarcopenia and Muscle 2016
DOI: 10.1002/jcsm.12157
